Treatment options for small cell lung cancer – do we have more choice?

Current treatment options for non-small-cell lung cancer.

Non-small-cell lung cancer (NSCLC) remains a difficult-to-treat malignancy, and durable long-term survival is elusive for patients with advanced-stage disease. Chemotherapy, especially with platinum-based combinations, is the mainstay of treatment, yet these regimens yield only modest response and survival rates. Outcomes of recent clinical trials have shown that histology, mutation analyses, a...

Ramadan fasting: Do we need more evidence?

Over a billion of Muslims fast worldwide during Ramadan each year. Through this religious custom, fasting contributes to their health as well as their spiritual growth. However, available evidence regarding the health-benefits of Ramadan fasting is scarce and highly contentious. Although Islam exempts patients from fasting, many fast conceivably, and their clinical condition is prone to deterio...

Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?

Surgery remains the initial treatment for patients with early-stage non-small-cell lung cancer (NSCLC). Additional therapy is necessary because of high rates of distant and local disease recurrence after surgical resection. Early trials of adjuvant chemotherapy and postoperative radiation were often plagued by small patient sample size, inadequate surgical staging, and ineffective or antiquated...

Cognitive Architecture: What Choice Do We Have?

Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it?

BACKGROUND Twenty percent of all newly diagnosed patients with small-cell lung cancer (SCLC) are >75 years. Elderly patients may show more toxicity due to co-morbidity. We evaluated motives for adherence to treatment guidelines, completion of treatment and toxicity. PATIENTS AND METHODS Population-based data from patients aged ≥75 years and diagnosed with SCLC in 1997-2004 in The Netherlands ...